CD19 and primary central nervous system lymphoma: Furthermore, chimeric antigen receptor T (CAR‐T) cell therapy has shown potential for treating CNS lymphoma, with anti‐CD19 CAR‐T cells yielding significant treatment responses in R/R PCNSL.31, 32